178 related articles for article (PubMed ID: 35041493)
21. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
22. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
[TBL] [Abstract][Full Text] [Related]
23. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Schöffski P; Reichardt P; Blay JY; Dumez H; Morgan JA; Ray-Coquard I; Hollaender N; Jappe A; Demetri GD
Ann Oncol; 2010 Oct; 21(10):1990-1998. PubMed ID: 20507881
[TBL] [Abstract][Full Text] [Related]
24. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
25. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
28. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
[TBL] [Abstract][Full Text] [Related]
29. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
Maurel J; Martins AS; Poveda A; López-Guerrero JA; Cubedo R; Casado A; Martínez-Trufero J; Ramón Ayuso J; Lopez-Pousa A; Garcia-Albeniz X; Garcia del Muro X; de Alava E
Cancer; 2010 Aug; 116(15):3692-701. PubMed ID: 20564079
[TBL] [Abstract][Full Text] [Related]
30. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB; Jagannathan JP; Kurra V; Urban T; Manola J; Choy E; Demetri GD; George S; Ramaiya NH
Eur J Cancer; 2014 Mar; 50(5):981-6. PubMed ID: 24388774
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
32. Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
Mohammadi M; IJzerman NS; Hollander DD; Bleckman RF; Oosten AW; Desar IME; Reyners AKL; Steeghs N; Gelderblom H
Target Oncol; 2023 May; 18(3):415-423. PubMed ID: 37079223
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
[TBL] [Abstract][Full Text] [Related]
34. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Zhou Y; Zhang X; Wu X; Zhou Y; Zhang B; Liu X; Wu X; Li Y; Shen L; Li J
Cancer Med; 2020 Sep; 9(17):6225-6233. PubMed ID: 32677196
[TBL] [Abstract][Full Text] [Related]
35. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Demetri GD; Casali PG; Blay JY; von Mehren M; Morgan JA; Bertulli R; Ray-Coquard I; Cassier P; Davey M; Borghaei H; Pink D; Debiec-Rychter M; Cheung W; Bailey SM; Veronese ML; Reichardt A; Fumagalli E; Reichardt P
Clin Cancer Res; 2009 Sep; 15(18):5910-6. PubMed ID: 19723647
[TBL] [Abstract][Full Text] [Related]
37. Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
Toulmonde M; Blay JY; Bouche O; Mir O; Penel N; Isambert N; Duffaud F; Bompas E; Esnaud T; Boidot R; Geneste D; Ghiringhelli F; Lucchesi C; Bellera CA; Le Loarer F; Italiano A
Clin Cancer Res; 2019 Aug; 25(15):4611-4615. PubMed ID: 30979737
[TBL] [Abstract][Full Text] [Related]
38. Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib.
Rutkowski P; Teterycz P; Klimczak A; Bylina E; Szamotulska K; Lugowska I
Tumori; 2018 Dec; 104(6):415-422. PubMed ID: 29714669
[TBL] [Abstract][Full Text] [Related]
39. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
Hu K; Zhang H; Shu M; Wang X
Cancer Med; 2023 Jun; 12(11):12187-12197. PubMed ID: 37084005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
